Short interest for Urban-gro gives investors a sense of the degree to which investors are betting on the decline of Urban-gro's stock. Short interest data is updated every two weeks.

Urban-gro Stock (NASDAQ:UGRO), Short Interest Report

Urban-gro

Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.

cannabis SNDL CGC TLRY ACB

Cannabis

Earnings

News

UGRO

Marijuana Ancillary Company Urban-Gro Quarterly Revenue Drops YoY, Improves Net Loss

Benzinga Cannabis Capital Conference in Florida on April 16 and 17, 2024

Mid Cap

Penny Stocks

Markets

When design-build provider to the cannabis industry Urban-Gro (NASDAQ: UGRO) announced its financial results Wednesday for the full year and 4Q 2024, the company&#39;s stock price plunged to $1.4 - a 23.42% decrease in just 24 hours

Cannabis Ancillary Company Urban-Gro&#39;s Stock Plunges On Reporting Q4 &amp; 2023 Results, Here&#39;s Why

Eurozone

Commodities

Global

Intraday Update

Trading Ideas

AVTX

BDRX

DTST

PMEC

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 15 points on Thursday.

The Dow traded up 0.06% to 39,785.29 while the NASDAQ fell 0.13% to 16,383.85. The S&amp;P 500 also rose, gaining, 0.10% to 5,253.70.

Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results

Urban-gro Inc

<p>BMO Capital  analyst Brian Pitz   reiterates Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Outperform and maintains $92 price target.</p>


Price Target

Reiteration

Analyst Ratings

UBER

BMO Capital Reiterates Outperform on Uber Technologies, Maintains $92 Price Target

<ul>
<li>Agreement with FDA reached on key elements to move forward with our international Phase 3 clinical trial program</li>
<li>Agreement also reached with FDA on complete non-clinical and clinical development plan for filing of a New Drug Application for marketing approval</li>
<li>Planning continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of <i>C. difficile </i>Infection (CDI)</li>
<li>SME (Small and Medium-sized Enterprise) designation has been granted by the EMA (European Medicines Agency), which allows Acurx to benefit from fee incentives and other support from the EMA for EU Marketing Authorization</li>
<li>Acurx is now preparing to submit requests for guidance to initiate clinical trials in the European Union, the United Kingdom, Japan and Canada
<ul>
<li>Ibezapolstat has previously received FDA QIDP and Fast-Track Designation from FDA</li>
</ul>
</li>
</ul>


Biotech

General

ACXP

Acurx Reports Outcome Of FDA End-of-Phase 2 Meeting And Phase 3 Readiness For Ibezapolstat For Treatment Of C. difficile Infection

<p>BMO Capital  analyst Kostas Biliouris   maintains Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Outperform and maintains $120 price target.</p>


KRRO

BMO Capital Maintains Outperform on Korro Bio, Maintains $120 Price Target

<p>Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.26 by 119.23 percent. This is a 2950 percent increase over losses of $(0.02) per share from the same period last year.  The company reported quarterly sales of $38.293 million which beat the analyst consensus estimate of $34.745 million by 10.21 percent.  This is a 112.43 percent increase over sales of $18.026 million the same period last year.</p>


Earnings Beats

SHIP

Seanergy Maritime Hldgs Q1 2024 Adj EPS $0.57 Beats $0.26 Estimate, Sales $38.293M Beat $34.745M Estimate

<p>Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) in the last three months.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $81.22, a high estimate of $90.00, and a low estimate of $72.00. Marking an increase of 11.52%, the current average surpasses the previous average price target of $72.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715778095_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Boston Scientific by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$73.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$85.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>John Eade</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$79.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Outperform</td>
<td>$77.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Boston Scientific compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Boston Scientific's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Boston Scientific's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BSX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Boston Scientific analyst ratings.</strong></a></p>
<h2>Get to Know Boston Scientific Better</h2>
<p>Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.</p>
<h3>Unraveling the Financial Story of Boston Scientific</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Boston Scientific showcased positive performance, achieving a revenue growth rate of <strong>13.78%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Boston Scientific's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>12.84%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Boston Scientific's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.53%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Boston Scientific's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>1.38%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Boston Scientific's debt-to-equity ratio is below the industry average at <strong>0.55</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 18 Analyst Evaluations For Boston Scientific

Financing

AQMS

Aqua Metals Signs $33M Non-Binding Loan Term Sheet

<p>Analysts' ratings for Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Analog Devices and provided 12-month price targets. The average target is $221.25, accompanied by a high estimate of $254.00 and a low estimate of $205.00. Observing a 3.39% increase, the current average has risen from the previous average price target of $214.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715778069_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Analog Devices among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$254.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$212.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$205.00</td>
<td>-</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$205.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$212.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Rick Schafer</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$222.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Toshiya Hari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$205.00</td>
<td>$191.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$205.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Analog Devices. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Analog Devices compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Analog Devices's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Analog Devices's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ADI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Analog Devices analyst ratings.</strong></a></p>
<h2>All You Need to Know About Analog Devices</h2>
<p>Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.</p>
<h3>Financial Milestones: Analog Devices's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Analog Devices's revenue growth over 3 months faced difficulties. As of 31 January, 2024, the company experienced a decline of approximately <strong>-22.68%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Analog Devices's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>18.42%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.3%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Analog Devices's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.95%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Analog Devices's debt-to-equity ratio is below the industry average. With a ratio of <b>0.2</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Key Takeaways From Analog Devices Analyst Ratings

<p><strong>Unipics </strong>also known as <strong>‘Bonk Guy',</strong> revealed a seven-figure profit in 48 hours trading <strong>AMC</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">AMC</a>) and <strong>GameStop</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">GME</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38523300/crypto-trader-michael-van-de-poppe-highlights-runs-in-solana-meme-coins-predicts-there-is-">derivatives on Solana</a>.</p>
<p><strong>What Happened:</strong> Bonk Guy disclosed that he invested around $155,000 in trade which is currently worth $1.3 million with an unrealized profit of $1.15 million (marking 641% gains). He made this money through his trade on AMC and GME meme coins on Solana, noting that the real "meme coin season" hasn&#8217;t even begun yet. According to Bonk Guy, there is potential for more explosive gains in the future.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">i&#39;m up 7 figures in 48 hours trading the <a href="https://twitter.com/search?q=%24AMC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$AMC</a> and <a href="https://twitter.com/search?q=%24GME&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GME</a> derivatives on Solana (on one of my wallets!)<br /><br />and i live tweeted my trade<br /><br />it&#39;s crazy to think that the real memecoin season hasn&#39;t even started yet<br /><br />things are going to get ridiculously explosive this cycle<br /><br />God willing <a href="https://t.co/KlOY6SFe6Z">https://t.co/KlOY6SFe6Z</a> <a href="https://t.co/li3JWvNX8O">pic.twitter.com/li3JWvNX8O</a></p>
<p>&mdash; Unipcs (aka &#39;Bonk Guy&#39;) &#x1f392; (@theunipcs) <a href="https://twitter.com/theunipcs/status/1790672697640317238?ref_src=twsrc%5Etfw">May 15, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Based on DEXScreener <a href="https://dexscreener.com/solana/hzzofxusqkaa9jqaexw8ptualrxuwsllwnt4ebfiyedc">data</a>, AMC/SOL is up 16,000% on the week, trading at a valuation of $17.1 million. GME is valued at $117 million, up 3,400% on the week. </p>
<p>These price gains put the two low-cap meme coins far ahead of the weekly performance of bigger meme coins, such as <strong>Dogecoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and <strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>).</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure></p>
<p><em>Also Read: <a href="https://www.benzinga.com/markets/equities/24/05/38835568/gamestop-amc-meme-stock-rally-not-driven-by-retail-traders-this-time-ig-north-america-ceo-says-i">Gamestop, AMC Meme Stock Rally Not Driven By Retail Traders This Time, IG North America CEO Says &#8216;I Do Not Get The Feeling&#8217;</a></em></p>
<p><strong>Why It Matters:</strong> Bonk Guy also suggested that if the narrative around AMC and GME remains strong, the stocks are likely to continue their upward trajectory. This could bring more attention to decentralized derivatives on Solana, especially as retail investors become more aware of these platforms.</p>
<p>The trader concludes with a word of caution for those considering entering the market now and emphasizes the importance of careful entry points in the volatile world of decentralized trading.</p>
<p><strong>What&#8217;s Next</strong>: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/equities/24/05/38837013/amid-gme-amc-rally-expert-says-first-time-this-happened-it-was-more-of-a-movement-but-right-now-">Amid GME, AMC Rally, Expert Says &#8216;First Time This Happened, It Was More Of A Movement, But Right Now This Looks Like A Craze&#8217;</a></em></p>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$AMC

$DOGE

$GME

$SHIB

Millionaire Trader 'Up 7 Figures In 48 Hours' On GameStop And AMC Meme Coins On Solana

<p>Crypto trader <strong>Intuitio </strong>declared the current market downturn a "bear trap," comparing it to the 2021 summer bear trap while noting the stronger positions of <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and <strong>Ethereum</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) this time around.</p>
<p><strong>What Happened:</strong> Intuitio <a href="https://twitter.com/intuitio_/status/1790487050854043791">asserts</a> that the present summer bear trap closely mirrors that of 2021. He points out that the bear trap in 2021 spanned from mid-April to mid-July, lasting three months. He adds that currently, we are two months into a similar bear trap.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price (April 15, 2024)</strong></td>
<td><strong>Current Price </strong></td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$62,919.10</td>
<td>$62,459.48</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,066.72</td>
<td>$2,898.83</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$134.46</td>
<td>$144.06</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.155273</td>
<td>$0.1491</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00002273</td>
<td>$0.00002363&nbsp;&nbsp;</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p>A significant observation is the pattern in altcoin performance. In 2021, most altcoins dropped by 60-70%, while now they are down about 60%. However, the strength of Bitcoin and Ethereum sets the current scenario apart. In 2021, Bitcoin fell by 55%, but it is now only down 20%. Similarly, Ethereum declined by 65% in 2021 but is only down 30% now.</p>
<p>Intuitio attributes this relative strength to the influence of cryptocurrency ETFs, which have bolstered the two leading cryptocurrencies. He states this as "an amazing sign of strength."</p>
<p>Reflecting on the aftermath of the 2021 bear trap, where quality altcoins surged 10x from their lows, Intuitio believes a similar rebound is imminent. "Bottom is very close. We are going to pump very soon. And yes, ETH will lift the whole market," he asserts.</p>
<p>However, he emphasizes that not all assets will perform equally, with some pumping more than others.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure></p>
<p><em>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38765514/crypto-expert-reveals-how-to-find-high-risk-high-reward-meme-coins">Crypto Expert Reveals How To Find &#8216;High-Risk High Reward&#8217; Meme Coins</a></em></p>
<p><strong>Why It Matters:</strong> Intuitio advises investors to remain focused and strategic, particularly on the fastest meme and AI coins, recommending concentrated bets on a maximum of four coins with big longs. He stresses the importance of the next six months, describing them as crucial for building significant positions in the market.</p>
<p>The trader suggests holding your ground, staying observant, and preparing for a surge in the crypto market. As he puts it, "Hold up your head and keep grinding," signaling that those who navigate wisely through this bear trap will emerge stronger in the impending market upswing.</p>
<p>However, Former Wall Street Macro Trader Wizard Of SoHo has a different <a href="https://twitter.com/wizardofsoho/status/1790440557291925630">viewpoint</a> on this. He states that it would be the biggest mistake to compare this cycle to 2021. He adds, "That cycle had trillions in stimulus and zero rates injected into the economy. This cycle has had zero new money injection."</p>
<p><strong>What&#8217;s Next</strong>: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38810829/trader-nets-a-553x-return-with-meme-coin-of-the-most-memeable-cat-on-the-internet">Trader Nets A 553X Return With Meme Coin Of &#8216;The Most Memeable Cat On The Internet&#8217;</a></em></p>
<p><em>This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p><em>Image created using artificial intelligence with Midjourney.</em></p>


$BTC

$ETH

$SOL

Why This Crypto Market Is 'A Bear Trap' And Which Coins This Trader Is Backing

<p>Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $13.4, along with a high estimate of $19.00 and a low estimate of $5.00. This current average reflects an increase of 14.82% from the previous average price target of $11.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715778057_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive WAVE Life Sciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$11.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to WAVE Life Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of WAVE Life Sciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for WAVE Life Sciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into WAVE Life Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WVE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on WAVE Life Sciences analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering WAVE Life Sciences: A Closer Look</h2>
<p>WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.</p>
<h3>WAVE Life Sciences: Delving into Financials</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining WAVE Life Sciences's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately <strong>-3.02%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> WAVE Life Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-251.7%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> WAVE Life Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-97.07%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> WAVE Life Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-12.37%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.2</strong>, WAVE Life Sciences faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Offerings

Aqua Metals Prices $7M Public Offering Of 17.5M Shares Of Common Stock And Non-Redeemable Warrants

<p>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.6, with a high estimate of $17.00 and a low estimate of $13.00. This current average has increased by 12.31% from the previous average price target of $13.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715778049_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of OptimizeRx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$17.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to OptimizeRx. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OptimizeRx compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of OptimizeRx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into OptimizeRx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OPRX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on OptimizeRx analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About OptimizeRx</h2>
<p>OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.</p>
<h3>OptimizeRx: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, OptimizeRx showcased positive performance, achieving a revenue growth rate of <strong>44.34%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> OptimizeRx's net margin excels beyond industry benchmarks, reaching <strong>-14.6%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> OptimizeRx's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-3.41%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> OptimizeRx's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-2.7%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> OptimizeRx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.29</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OPRX

Expert Ratings For OptimizeRx

<p>BMO Capital  analyst Brian Pitz   reiterates Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Outperform and maintains $215 price target.</p>


GOOGL

BMO Capital Reiterates Outperform on Alphabet, Maintains $215 Price Target

<p>Across the recent three months, 6 analysts have shared their insights on Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Absci, presenting an average target of $8.83, a high estimate of $13.00, and a low estimate of $7.00. This current average reflects an increase of 26.14% from the previous average price target of $7.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715778036_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Absci's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$9.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Absci. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Absci compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Absci's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Absci's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ABSI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Absci analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Absci: A Closer Look</h2>
<p>Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.</p>
<h3>Absci's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Challenges:</strong> Absci's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately <strong>-78.29%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-6965.98%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Absci's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-12.64%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Absci's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-10.38%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.09</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ABSI

The Analyst Verdict: Absci In The Eyes Of 6 Experts

<p>Vertiv Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Vertiv Hldgs, presenting an average target of $90.8, a high estimate of $115.00, and a low estimate of $56.00. Witnessing a positive shift, the current average has risen by 19.25% from the previous average price target of $76.14.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715778019_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Vertiv Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$96.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Stephen Trent</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$56.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Vertiv Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Vertiv Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Vertiv Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Vertiv Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VRT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Vertiv Hldgs analyst ratings.</strong></a></p>
<h2>About Vertiv Hldgs</h2>
<p>Vertiv Holdings Co brings together hardware, software, analytics and ongoing services to ensure its customers vital applications run continuously, perform optimally and grow with their business needs. The company solves the important challenges faced by data centers, communication networks and commercial and industrial facilities with a portfolio of power, cooling and IT infrastructure solutions and services that extends from the cloud to the edge of the network. Its services include critical power, thermal management, racks and enclosures, monitoring and management, and other services. Its three business segments include the Americas, Asia Pacific; and Europe, Middle East &amp; Africa.</p>
<h3>Vertiv Hldgs: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Vertiv Hldgs showcased positive performance, achieving a revenue growth rate of <strong>7.76%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Vertiv Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.36%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-0.35%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Vertiv Hldgs's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.08%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.25</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings For Vertiv Hldgs

<p>Formerly disgraced FTX CEO and Co-Founder Sam Bankman-Fried was convicted in November of wire fraud, money laundering and conspiracy, and sentenced to 25 years in prison. His high-profile trial marked a significant chapter in the unraveling of FTX, which collapsed under suspicious financial practices, leading to intense scrutiny and legal action.</p>
<p>For the first time since his incarceration, Bankman-Fried described his daily life in a detailed interview with journalist William D. Cohan of Puck.&nbsp;</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>Startup behind ‘the #1 free contractor app' grows 162% YoY,</strong><a href="https://www.benzinga.com/go/contractor-offering"><strong> </strong><strong>opens its doors for investors at a $100 minimum</strong></a><strong>.</strong></li>
<li><strong>Invest in time-tested solution that aims to solve this $600 billion women&#8217;s health problem</strong><a href="https://www.benzinga.com/money/rootless"><strong> </strong><strong>at 80 cents per share</strong></a><strong>.</strong></li>
</ul>
<p>Once accustomed to the breathtaking ocean views from his Bahamian mansion, he now resides in a cell with 35 other inmates, many of whom have serious criminal backgrounds.</p>
<p>Despite the drastic change, Bankman-Fried expressed that he does not "fear for his safety."</p>
<p>His days are primarily spent watching television and playing games on a tablet, a significant downgrade from his previous luxurious lifestyle.&nbsp;</p>
<p>However, his biggest challenge seems to be adjusting to the prison diet. Being a vegan, he finds the available food options "inedible" and subsists on a diet of rice and beans, with rice becoming a valuable commodity for exchange within the prison walls.</p>
<p><strong>Trending: Invest like a millionaire. Exclusive opportunity to</strong><a href="https://www.benzinga.com/money/epic-games"><strong> </strong><strong>invest in Epic Games $17 billion gaming empire.</strong></a></p>
<p>Bankman-Fried has <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/37356622/sam-bankman-fried-appeals-for-reduced-prison-term-seeks-63-78-months-citing-non-violent-of">continued maintaining his innocence,</a> telling Cohan that he "did not do anything wrong" and plans to appeal his conviction.</p>
<p>This interview comes right when <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38699358/ftx-to-pay-back-customers-in-full-with-interest-as-it-amasses-billions-in-cash-this-is-jus">FTX has filed its bankruptcy plans.&nbsp;</a></p>
<p>The plans aim for comprehensive distribution of assets to creditors globally, aligning with the liquidation of assets estimated between $14.5 and $16.3 billion. This arrangement suggests full recovery for creditors, including interest.&nbsp;</p>
<p>"We are pleased to be in a position to propose a Chapter 11 plan that contemplates the return of 100 percent of bankruptcy claim amounts plus interest for nongovernmental creditors," said John Ray III, Chief Executive Officer and Chief Restructuring Officer of FTX in the news release. "I want to thank all the customers and creditors of FTX for their patience throughout this process."</p>
<p><a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38723669/not-every-ftx-customer-is-happy-to-be-reimbursed-heres-why">However, not all creditors are satisfied with these developments. </a>Arush Sehgal, representing a group of creditors, criticized the proposed payouts, describing them as based on "a fake baseline" and calling them "an insult to creditors."</p>
<p>This dissatisfaction highlights ongoing tensions and mistrust among those financially impacted by FTX&#8217;s downfall.</p>
<p>Bankman-Fried&#8217;s story is a dramatic illustration of the rise and fall associated with the volatile cryptocurrency market. From the heights of financial success to the depths of legal and personal turmoil, his journey reflects broader issues in the tech and financial sectors.&nbsp;</p>
<p><strong>Keep Reading:</strong></p>
<ul>
<li><strong>Amid the ongoing EV revolution, previously overlooked low-income communities</strong><a href="https://www.benzinga.com/money/dunamis-1"><strong> </strong><strong>now harbor a huge investment opportunity</strong></a><strong>.</strong></li>
<li><strong>Here is where</strong><a href="https://www.benzinga.com/money/ourcrowd"><strong> </strong><strong>your most successful angel investment</strong></a><strong> may be hidden.</strong></li>
</ul>


Sam Bankman-Fried Traded In His $35 Million Mansion In The Bahamas For A Prison Cell With 35 Inmates But Claims "He Did Not Do Anything Wrong"

<p><em>Editor&#8217;s Note: The Tesla ticker has been corrected to TSLA.</em></p>
<p>Trading expert and author <strong>Anne-Marie Baiynd</strong> joined Benzinga's YouTube on Tuesday to discuss current option trade ideas. Baiynd highlighted three separate potential <strong>Tesla Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) option trades on the show that could help investors <a href="https://www.benzinga.com/topic/tesla">boost their returns.</a></p>
<p>Baiynd and host <strong>Ryan Faloona</strong> discussed President <strong>Joe Biden</strong>'s decision to increase tariffs on Chinese EVs to 100% as a positive catalyst for Tesla and other American EV companies like <strong>Rivian Motors</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>).</p>
<p>Baiynd, the author of &#8220;The Trading Book: A Complete Solution to Mastering Technical Systems and Trading Psychology,&#8221; then shared her charts and how she was looking to play Tesla's positive price action.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="$GME $AMC Live Stock Trading With Benzinga &#x7C; May 14th, 2024" width="500" height="281" src="https://www.youtube.com/embed/-XO2hxoyGHU?start=6798&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p>"Let's say that the price action moves all the way up into $185, and it holds the low action event of $168 where it moved on the pullback down," Baiynd said. "The easiest way with the most reward and the least risk&#8230; is to say &#8216;alright I'm going to take the floor of that short put and I'm going to go to the $160 area, and it's going to give me $1.67.'&#8221;</p>
<p>The trade that Baiynd described is a short-put vertical. These options spread strategy is a bullish strategy that allows traders to make money if the stock doesn't move, or moves higher.</p>
<p>In a more bullish trade, Baiynd outlined a butterfly spread, in which she sold a $193.33 call and bought a $185 and $200 call. The total cost of putting this trade on was slightly over $1.28 (which comes out to $128 per contract).</p>
<p>"As long as this gets to $185 we're very likely to double our money," Baiynd said.</p>
<p>To watch Baiynd's <a href="https://www.youtube.com/live/-XO2hxoyGHU?si=c9Yy60XK16rML88z&amp;t=6794">full trade ideas on Tesla options, click here</a>. Also, you can check out Baiynd's chat room <a href="https://www.benzinga.com/pro/register?utm_source=anne-marie-show">where she gives more trade ideas here.&nbsp;</a></p>
<p><em>Now Read:<a href="https://www.benzinga.com/news/24/05/38838705/jpmorgans-jamie-dimon-urges-full-engagement-with-china-amid-bidens-new-tariffs-but-says-america-has"> JPMorgan&#8217;s Jamie Dimon Urges &#8216;Full Engagement&#8217; With China Amid Biden&#8217;s New Tariffs, But Says &#8216;America Has The Right To Do Things To Protect Itself&#8217;</a></em></p>
<p><em>Image generated using artificial intelligence via Midjourney.</em></p>


Options

Exclusives

Tech

RIVN

TSLA

EXCLUSIVE: Top Tesla Options Trades Recommended By Trading Expert (UPDATED)

<p>BMO Capital  analyst Brian Pitz   maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Market Perform and maintains $145 price target.</p>


EXPE

BMO Capital Maintains Market Perform on Expedia Group, Maintains $145 Price Target

Stock Split

CTHR

Charles & Colvard Announces 1-for-10 Reverse Stock Split Effective May 17, 2024; Aims To Comply With Nasdaq's $1.00 Minimum Bid Price Requirement; Split-Adjusted Trading To Begin On May 17, 2024

<p>BMO Capital  analyst Etzer Darout   reiterates Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) with a Outperform and maintains $25 price target.</p>


ACRV

BMO Capital Reiterates Outperform on Acrivon Therapeutics, Maintains $25 Price Target

These Industrials stocks are trading higher:-Virtra Inc (VTSI) stock is trading at $12.86, an increase of $3.32, or 34.8%, on high volume.  Virtra Systems Inc gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $13.75.  -urban-gro

Industrials Stocks Moving Up and Down Tuesday: VTSI, UGRO, CVV, CETY, PPSI, DCFC, GE, UP

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>There are many high-quality businesses trading near $10 per share that have significant growth potential ahead as their core operations continue to expand at a rapid pace. While their stock prices remain depressed and languishing, the intrinsic values of these companies are poised for major upside. With smart stock picking, these small-cap gems could deliver outsized multibagger returns for investors willing to take on some risk.</p>



<p>Many of these sub-$10 stocks do come with higher risk profiles. However, by targeting companies that are at or near profitability with established share prices, the upside potential often outweighs the downside risks. These businesses are trading at bargain valuations compared to their growth prospects. Once the market takes notice, significant gains could be in store.</p>



<p>Moreover, with interest rate cuts potentially on the horizon this year, we may see a surge in growth for small-cap companies. Rate cuts could provide just the catalyst needed to ignite a rally in these overlooked gems. Now is the time to take a closer look before they take off.</p>



<h2>Urban-Gro, Inc. (UGRO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/ugro-stock-1600-300x169.jpg" alt="LED lighting used to grow lettuce inside a warehouse without the need for sunlight"><div>Source: Martin Bergsma / Shutterstock.com</div></div><p><strong>Urban-Gro</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ugro-stock-quote/"><strong>UGRO</strong></a>) is an integrated professional services and design-build firm that offers value-added architectural, engineering, and construction management solutions to the Controlled Environment Agriculture (<span>CEA</span>), industrial, healthcare, and other commercial sectors. It also provides complex environmental equipment systems for high-performance indoor cannabis cultivation facilities globally. I believe this company can benefit significantly from the ongoing industrial expansion and infrastructure boom in the United States.</p>



<p>UGRO is expected to see its losses start to narrow substantially, along with <a href="https://seekingalpha.com/symbol/UGRO/earnings/estimates">revenue growing from $82 million in 2024 to $208 million in 2028</a> based on current projections. The company currently trades at a forward price-to-sales ratio of just 0.24 times, which I believe is exceptionally cheap. This is mostly due to the fact that Urban-Gro has a $5.3 million debt load, which is quite sizable compared to its $20 million market capitalization. However, I think that once interest rates are cut and the company reaches a positive margin, we could see huge stock price appreciation ahead for UGRO.</p>



<h2>FullNet Communications, Inc. (FULO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/small-cap-picks-300x169.jpg" alt='a journal that says "Small is the new BIG" to represent small-cap stocks in index funds. Small-Cap Stocks with Potential'><div>Source: Shutterstock</div></div><p><strong>FullNet Communications</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/fulo-stock-quote/"><strong>FULO</strong></a>) provides integrated communications services in the United States, including mass notification services, carrier-neutral equipment colocation services, Internet access, web hosting, customized live help desk outsourcing services, and voice and data solutions. The stock is currently off 78% from its peak, but I have strong conviction in FULO at current levels.</p>



<p>In my view, FULO stock is bottoming out and making a turnaround in parallel to improving financials. Despite its tiny $5 million market cap, FULO is a very strong company fundamentally. Not only is it profitable with a <a href="https://www.gurufocus.com/term/FCFmargin/FULO">16.5% free cash flow margin</a> (better than 81% of telecom peers), but FULO also pays a dividend that yields 5.7%. It trades at just 11 times earnings, and the company has 22 times more cash than debt on its balance sheet. I believe FULO stock can easily deliver multibagger gains for investors once it makes a full turnaround from here, especially as large telecom companies recover and restart expansion plans.</p>



<h2>Olo (OLO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/stocks-to-buy-1600-300x169.jpg" alt="Stocks to buy: smartphone with the words &quot;buy&quot; and &quot;sell&quot; displayed on the screen. The user's finger is about to press buy. Stock charts are in the background of the image. Momentum Stocks. S&amp;P 600 Stocks to Buy. breakthrough stocks. Mario Gabbeli stocks"><div>Source: Chompoo Suriyo / Shutterstock.com</div></div><p><strong>Olo</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/olo-stock-quote/"><strong>OLO</strong></a>) is a B2B SaaS company that operates an open platform for restaurants in the United States, enabling on-demand digital commerce operations including digital ordering, delivery, front-of-house management, and payments. The stock doesn&rsquo;t have the prettiest stock chart recently, and near-term losses are causing the stock to continue declining. However, I believe this company could make a turnaround soon as margins return to positive territory and start expanding again.</p>



<p>In Q4, Olo <a href="https://www.google.com/finance/quote/OLO:NYSE">saw 26.6% year-over-year revenue growth</a>, which beat estimates by 7%. Moreover, analysts <a href="https://seekingalpha.com/symbol/OLO/earnings/estimates">expect 20 cents in EPS for 2024</a>, which is then expected to climb to 43 cents in 2026 EPS. That means you&rsquo;re paying just 11 times 2026 EPS estimates, which looks very cheap to me. Revenue is also expected to climb from $271 million to $400 million during this timeframe. With the global restaurant management software market expected to reach $15.3 billion by 2030, there is substantial long-term growth potential as well. <em>Gurufocus</em> puts OLO&rsquo;s fair value price at $18 by the end of 2026 for this penny stock.</p>



<h2>SelectQuote, Inc. (SLQT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/insurance-300x169.jpg" alt="Man in suit with hands over paper cutouts of family, car and home. Represents insurance."><div>Source: thodonal88 / Shutterstock.com</div></div><p><strong>SelectQuote</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/slqt-stock-quote/"><strong>SLQT</strong></a>) operates a direct-to-consumer platform in the U.S., selling a range of insurance products and healthcare services. It operates through three segments: Senior, Life, and Auto &amp; Home, distributing policies like <strong>Medicare Advantage</strong>, term life, and homeowners insurance. What differentiates SelectQuote from traditional insurance brokers is its distribution platform, which seamlessly blends technology and agent/human interaction components.</p>



<p>This company does not have the cleanest balance sheet, but I believe it has significant growth potential and looks attractively valued here. In my view, SLQT can deliver multibagger returns from current levels as it trades at a P/S ratio of just 0.25 times. Like many high-growth startups, its stock was decimated from mid-2021 to mid-2022, trading sideways around $1-$2 per share for months. However, I think SelectQuote is poised for a breakout as its financials continue improving.</p>



<p>In Q4, the company&rsquo;s revenue <a href="https://www.google.com/finance/quote/SLQT:NYSE">surged 27% to $405 million</a>, beating analyst estimates by a whopping 7.7%. Yet, the stock remains range-bound, likely due to concerns over its $724 million debt load and mere $22 million in cash. However, SelectQuote is aggressively cutting losses, with declines expected to shrink 43% in 2024 and a further 63% in 2025, before reaching profitability in 2026. Rate cuts could also boost its path to profitability going forward.</p>



<h2>U &amp; I Financial Corp (UNIF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/strong-buy-stocks-300x169.jpg" alt='A tickerboard of various stocks, all rated "Strong Buy"'><div>Source: Shutterstock</div></div><p><strong>U &amp; I Financial</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/unif-stock-quote/"><strong>UNIF</strong></a>) is a bank holding company for <strong>UniBank</strong>, providing banking products and services to small to medium-sized businesses, professionals, and residents, with a focus on Korean and other ethnic minority communities in the U.S. It offers checking, savings, money market accounts, and commercial loans. This stock recently plunged from over $10 to $7 due to near-term issues. However, I see significant appreciation potential over the long run as the balance sheet and growth here look very strong.</p>



<p>UNIF&rsquo;s <a href="https://www.gurufocus.com/stock/UNIF/summary">cash-to-debt ratio stands at 7.4</a>, and it also has a net margin of over 38%. The P/E ratio is at just 3.5x, which is better than 95% of banks. That&rsquo;s despite a 3-year revenue growth rate of 16.6% annually, which also outpaces 81% of banks. The 3-year FCF growth rate here is 62%. <em>Gurufocus</em> sees a fair value price of $26.2 by the end of 2027 for UNIF.</p>



<h2>S4 Capital plc (SCPPF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/stocks-to-buy-2-300x169.jpg" alt="BUY spelled out on a computer keyboard representing stocks to buy"><div>Source: Shutterstock</div></div><p><strong>S4 Capital</strong> (OTCMKTS:<span><a href="https://investorplace.com/stock-quotes/scppf-stock-quote/"><strong>SCPPF</strong></a></span>) is a digital advertising and marketing services company operating across the Americas, Europe, Middle East, Africa, and Asia Pacific. It offers services including content creation for media platforms, campaign management analytics, creative production, ad serving, and digital transformation.</p>



<p>This stock was down 96% off its 2021 peak at one point, and the chart is definitely ugly on a long-term view. However, it seems to be bottoming out and recovering recently. Management does not expect much growth in 2024 but does expect the decline to slow. A lot of the negatives seem priced in right now, but there is huge potential for margin expansion. SCPPF has a <a href="https://www.gurufocus.com/term/grossmargin/SCPPF">gross margin of 86%</a> but a net margin of -0.6%. Thus, analysts see around 29% annual EPS growth (minus non-recurring items) over the next three to five years. We could see a major re-rating once the headwinds clear and SCPPF returns to growth.</p>



<h2>Century Casinos (CNTY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/century_casinos_cnty1600-300x169.jpg" alt="webpage of century casinos (CNTY), stocks under $20"><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p><strong>Century</strong> <strong>Casinos</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnty-stock-quote/"><strong>CNTY</strong></a>) focuses on investing in, developing, and operating regional mid-size casinos in North America. It offers entertainment in its casinos, racetracks, hotels, restaurants, bars, showrooms, event venues, comedy clubs, and golf courses. This is another stock I have high conviction in and believe buying on weakness is a good idea.</p>



<p>The stock has declined to a valuation below even its COVID trough. I believe it is likely to bottom out soon. Despite the company delivering solid growth and beating Q4 expectations with EPS 22% higher than expected and <a href="https://www.google.com/finance/quote/CNTY:NASDAQ">38.6% revenue growth</a> topping estimates by 1%, the stock hasn&rsquo;t recovered much. CNTY is still unprofitable, but profitability could come soon. Its <a href="https://www.gurufocus.com/term/ebitda_growth_3y/CNTY">3-year EBITDA growth rate is 55.4%</a>. Analysts expect it to turn EPS positive in 2026. The losses until then seem manageable, and CNTY has a $171 million cash buffer to cover those losses. The decline has caused it to trade at just 0.15 times sales, and I don&rsquo;t expect it to slide down much further from here.</p>



<p><em>On the date of publication, Omor Ibne Ehsan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a></em></p>
<div><p>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/7-small-cap-gems-under-10-primed-for-1000-growth/">7 Small-Cap Gems Under $10 Primed for 1,000% Growth</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Small-Cap Gems Under $10 Primed for 1,000% Growth

ATI, Lichen China, H&E Equipment Services among industrial movers

urban-gro Non-GAAP EPS of -$0.12, revenue of $15.5M

urban-gro, Inc. (UGRO) Q1 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Urban-gro</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ugro-stock-quote/"><strong>UGRO</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Urban-gro reported earnings per share of -12 cents. This was above the analyst estimate for EPS of -17 cents.</li><li>The company reported revenue of $15.54 million.</li><li>This was 2.73% better than the analyst estimate for revenue of $15.13 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/ugro-stock-earnings-urban-gro-for-q1-of-2024/">UGRO Stock Earnings: Urban-gro Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

UGRO Stock Earnings: Urban-gro Beats EPS, Beats Revenue for Q1 2024

Craig-Hallum analyst Eric Des Lauriers reiterated a Buy rating on urban-gro (UGRO – Research Report) today and set a price target of $3.25. The com...

Craig-Hallum Sticks to Their Buy Rating for urban-gro (UGRO)

urban-gro (UGRO – Research Report), the Industrials sector company, was revisited by a Wall Street analyst yesterday. Analyst Anthony Vendetti from...

Buy Rating on Urban-gro Backed by Solid Financials and Favorable Regulatory Outlook

Manitex International, Energy Services of America, Safe & Green among industrial movers

CETY

CNTY

DCFC

ESOA

FPAY

FULO

LICN

LNZA

MNTX

NEOV

PPSI

SCPPF

SGBX

SLQT

SUGP

TAYD

UNIF

VRME

VTSI

Press Releases

urban-gro, Inc. to Report Third Quarter 2023 Earnings Results on November 9, 2023

urban-gro, Inc. Reports Third Quarter 2023 Financial Results Demonstrating Sequential Improvement in Revenue, Backlog, and Adjusted EBITDA

Contracts

urban-gro, Inc. Awarded $9.6 Million Industrial Design-Build Contract with Existing CPG Client

urban-gro, Inc. Finalizes $10 Million Interest-Only Revolving Asset-Based Lending Facility

urban-gro, Inc. Secures Design-Build Contract Valued at Approximately $20 Million

urban-gro, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 27, 2024

urban-gro, Inc. Reports 2023 Financial Results and Provides Outlook on 2024 Performance

urban-gro, Inc. to Report First Quarter 2024 Financial Results on April 30, 2024

urban-gro, Inc. Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Guidance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Urban-gro Stock (NASDAQ:UGRO), Short Interest Report

People Also Watch